Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -31.36% is 97% above its 4-year average of -1108.96%, near the high end of its 4-year range (-18613.51%–1143.29%).
69.81% above its 12-month average of -103.86%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -223.17%.
EBITDA MARGIN
-31.36%
EBITDA MARGIN AVG TTM
-103.86%
EBITDA MARGIN AVG 3Y
-348.31%
EBITDA MARGIN AVG 5Y
-1108.96%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+69.81%
CURRENT VS 3Y AVG
+91.00%
CURRENT VS 5Y AVG
+97.17%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Verrica Pharmaceuticals Inc.
Market Cap
$70.60M
EBITDA Margin
-31.36%
TTM Avg
-103.86%
3Y Avg
-348.31%
5Y Avg
-1108.96%
Market Cap
$72.36M
EBITDA Margin
-85.70%
TTM Avg
-57.28%
3Y Avg
-59.72%
5Y Avg
-51.35%
Market Cap
$71.15M
EBITDA Margin
-40176.79%
TTM Avg
-26409.54%
3Y Avg
-18300.96%
5Y Avg
-13878.09%
Market Cap
$74.03M
EBITDA Margin
-257.20%
TTM Avg
-292.35%
3Y Avg
-520.13%
5Y Avg
-2376.66%
Market Cap
$75.39M
EBITDA Margin
-58.13%
TTM Avg
-62.55%
3Y Avg
-79.72%
5Y Avg
-85.39%
Market Cap
$75.75M
EBITDA Margin
1.51%
TTM Avg
-4.98%
3Y Avg
-8.74%
5Y Avg
-7.62%
Market Cap
$69.19M
EBITDA Margin
-0.04%
TTM Avg
-76.47%
3Y Avg
-54.24%
5Y Avg
-650.20%
Market Cap
$68.40M
EBITDA Margin
-8394.83%
TTM Avg
-8394.83%
3Y Avg
-4949.66%
5Y Avg
-3042.42%
Market Cap
$77.15M
EBITDA Margin
-43906.17%
TTM Avg
-45201.13%
3Y Avg
-29968.45%
5Y Avg
-38423.13%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | $70.60M | -31.36% | -103.86% | -348.31% | -1108.96% |
| MindWalk Holdings Corp. (HYFT)vs › | $72.36M | -85.70% | -57.28% | -59.72% | -51.35% |
| Gain Therapeutics, Inc. (GANX)vs › | $71.15M | -40176.79% | -26409.54% | -18300.96% | -13878.09% |
| Hyperfine, Inc. (HYPR)vs › | $74.03M | -257.20% | -292.35% | -520.13% | -2376.66% |
| Pulmonx Corporation (LUNG)vs › | $75.39M | -58.13% | -62.55% | -79.72% | -85.39% |
| SkinHealth Systems Inc. (SKIN)vs › | $75.75M | 1.51% | -4.98% | -8.74% | -7.62% |
| Spero Therapeutics, Inc. (SPRO)vs › | $69.19M | -0.04% | -76.47% | -54.24% | -650.20% |
| Tiziana Life Sciences Ltd (TLSA)vs › | $68.40M | -8394.83% | -8394.83% | -4949.66% | -3042.42% |
| Sera Prognostics, Inc. (SERA)vs › | $77.15M | -43906.17% | -45201.13% | -29968.45% | -38423.13% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $76.50M | -145368.18% | -145368.18% | -145368.18% | -145368.18% |
Gross Margin
85.9%
EBITDA Margin
-31.4%
Operating Margin
-33.6%
Net Margin
-102.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -223.17% |
| 2026-03-31 | -189.55% |
| 2025-12-31 | -132.68% |
| 2025-09-30 | 12.63% |
| 2025-06-30 | 13.45% |
| 2025-03-31 | -230.36% |
| 2024-12-31 | -3243.31% |
| 2024-09-30 | 1143.29% |
| 2024-06-30 | -287.27% |
| 2024-03-31 | -477.23% |
| 2023-12-31 | -1156.19% |
| 2023-09-30 | -812.72% |
| 2023-06-30 | -6268.68% |
| 2023-03-31 | -18613.51% |
| 2022-12-31 | -8941.18% |
| 2022-09-30 | 21.26% |
| 2022-06-30 | -4216.36% |
| 2022-03-31 | -1696.52% |
| 2021-03-31 | 1.06% |
